Conference Report

Genitourinary and Noncolorectal Gastrointestinal Malignancies

Source: CCO Independent Conference Coverage of the 2008 Annual Meeting of the European Society for Medical Oncology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Genitourinary and Noncolorectal Gastrointestinal Malignancies

Faculty:

Eric Van Cutsem, MD, PhD
Cora N. Sternberg, MD, FACP

CREDIT INFORMATION

Release Date: 11/12/08

Expiration Date: 11/11/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize recent clinical trial data regarding mTOR inhibition in renal cell carcinoma and neuroendocrine tumors
Discuss the use of tyrosine kinase inhibitors in the setting of genitourinary and gastrointestinal tumors
Describe anti-VEGF therapy for the treatment of renal cell carcinoma and hepatocellular carcinoma
Summarize data on therapeutic approaches in imatinib-resistant patients

Topics covered include:

Sunitinib vs Interferon alfa in the First-Line Treatment of Metastatic RCC
Predictive and Prognostic Factors Associated With Pazopanib, a Multikinase Angiogenesis Inhibitor
Long-term Tolerability of Bevacizumab in Metastatic Renal Cell Carcinoma
mTOR Inhibition With Everolimus in Metastatic Renal Cell Carcinoma
Vinflunine in the Second-Line Treatment of Transitional Cell Carcinoma of the Urothelium
Paclitaxel, Cisplatin, and Gemcitabine as Rescue Therapy in Male Germ-Cell Tumors
Bevacizumab and Sorafenib in Hepatocellular Carcinoma
Lipid-Complexed Paclitaxel Plus Gemcitabine in Pancreatic Cancer
Sunitinib in Gastrointestinal Stromal Tumors: Confronting Resistance
Everolimus With or Without Octreotide in Chemotherapy-Refractory Neuroendocrine Tumors

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.